Amneal Pharmaceuticals, Inc.
AMRX
$10.48
$0.121.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.38M | -13.05M | -116.89M | -184.45M | -174.62M |
| Total Depreciation and Amortization | 245.36M | 240.82M | 236.19M | 226.99M | 225.24M |
| Total Amortization of Deferred Charges | 41.56M | 42.14M | 42.13M | 20.36M | 21.28M |
| Total Other Non-Cash Items | 137.64M | 135.48M | 137.73M | 222.17M | 230.29M |
| Change in Net Operating Assets | -76.87M | -98.47M | -4.07M | 27.78M | -49.73M |
| Cash from Operations | 351.08M | 306.92M | 295.10M | 312.84M | 252.46M |
| Capital Expenditure | -80.20M | -64.40M | -60.34M | -49.67M | -45.03M |
| Sale of Property, Plant, and Equipment | 1.38M | 524.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 7.01M | 11.99M | 11.99M | 4.99M | 4.99M |
| Other Investing Activities | -9.30M | -9.15M | -14.65M | -33.95M | -31.35M |
| Cash from Investing | -81.12M | -61.03M | -63.00M | -78.63M | -71.39M |
| Total Debt Issued | 218.00M | 218.00M | 48.00M | 374.73M | 384.73M |
| Total Debt Repaid | -393.82M | -405.27M | -233.12M | -440.15M | -416.89M |
| Issuance of Common Stock | 1.52M | 1.20M | 1.15M | 1.05M | 837.00K |
| Repurchase of Common Stock | -22.41M | -22.38M | -7.95M | -7.72M | -7.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -37.70M | -19.35M | -19.88M | -179.32M | -206.62M |
| Cash from Financing | -234.40M | -227.80M | -211.79M | -251.42M | -245.66M |
| Foreign Exchange rate Adjustments | -1.51M | -1.30M | -999.00K | -58.00K | -366.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.05M | 16.78M | 19.31M | -17.26M | -64.96M |